Skip to main content

Table 4 Conditional logistic regression models to estimate the association between quintiles of PBDEs and PBB-153 plasma levels expressed in ng/L and breast cancer risk: adjusted odds ratios (ORs) and 95% confidence intervals (CIs) (E3N cohort, N = 394)

From: Plasma concentration of brominated flame retardants and postmenopausal breast cancer risk: a nested case-control study in the French E3N cohort

ng/L plasma  Model 0P trendModel 1P trendModel 2P trend
Number (%)
controls
Number (%) casesOR [95% CI]OR [95% CI]OR [95% CI]
PBDE sum197197      
 Q139(19.80)37(18.78)Reference0.97Reference0.66Reference0.59
 Q239(19.80)36(18.27)0.99 [0.53; 1.84] 1.09 [0.52; 2.26] 1.14 [0.54; 2.41] 
 Q340(20.30)38(19.29)1.01 [0.56; 1.82] 1.00 [0.51; 1.94] 1.02 [0.52; 2.00] 
 Q439(19.80)44 (22.34)1.18 [0.64; 2.18] 1.20 [0.59; 2.44] 1.20 [0.59; 2.46] 
 Q540(20.30)42 (21.32)1.10 [0.58; 2.08] 1.13 [0.54; 2.39] 1.21 [0.57; 2.58] 
log-PBDE sum  0.98 [0.67; 1.42]0.90.95 [0.62; 1.46]0.830.97 [0.63; 1.50]0.88
BDE-28197197      
 Q139(19.80)34 (17.26)Reference0.32Reference0.47Reference0.54
 Q239(19.80)40 (20.30)1.16 [0.62–2.18] 1.39 [0.67–2.90] 1.36 [0.65–2.85] 
 Q340(20.30)34 (17.26)0.99 [0.51–1.91] 0.92 [0.43–1.97] 0.99 [0.46–2.14] 
 Q439(19.80)41 (20.81)1.18 [0.62–2.26] 1.29 [0.61–2.72] 1.32 [0.63–2.80] 
 Q540(20.30)48 (24.37)1.36 [0.72–2.53] 1.33 [0.65–2.70] 1.27 [0.62–2.60] 
log-BDE-28  1.04 [0.80; 1.37]0.751.00 [0.74; 1.35]0.980.97 [0.72; 1.33]0.87
BDE-47197197      
 Q139(19.80)41 (20.81)Reference0.72Reference0.81Reference0.72
 Q239(19.80)34 (17.26)0.82 [0.43–1.56] 0.71 [0.35–1.47] 0.73 [0.35–1.53] 
 Q340(20.30)38 (19.29)0.91 [0.50–1.67] 0.98 [0.49–1.95] 1.01 [0.50–2.05] 
 Q439(19.80)40 (20.30)0.97 [0.53–1.79] 0.84 [0.42–1.67] 0.83 [0.41–1.69] 
 Q540(20.30)44 (22.34)1.06 [0.57–1.95] 1.05 [0.52–2.11] 1.11 [0.54–2.26] 
log-BDE-47  0.94 [0.70; 1.25]0.660.92 [0.66; 1.29]0.640.94 [0.67; 1.32]0.72
BDE-99197197      
 Q139(19.80)31 (15.74)Reference0.55Reference0.66Reference0.66
 Q239(19.80)45 (22.84)1.50 [0.77–2.90] 1.30 [0.62–2.73] 1.23 [0.57–2.62] 
 Q340(20.30)38 (19.29)1.27 [0.64–2.50] 1.26 [0.59–2.71] 1.32 [0.60–2.90] 
 Q439(19.80)41 (20.81)1.38 [0.70–2.72] 1.20 [0.56–2.56] 1.09 [0.50–2.38] 
 Q540(20.30)42 (21.32)1.36 [0.69–2.66] 1.28 [0.59–2.75] 1.29 [0.59–2.83] 
log-BDE-99  1.04 [0.78; 1.39]0.791.06 [0.76; 1.48]0.721.07 [0.77; 1.49]0.69
BDE-100197197      
 Q139(19.80)49 (24.87)Reference0.53Reference0.41Reference0.46
 Q239(19.80)36 (18.27)0.71 [0.38–1.33] 0.56 [0.27–1.17] 0.59 [0.28–1.27] 
 Q340(20.30)29 (14.72)0.54 [0.28–1.05] 0.42 [0.19–0.92] 0.42 [0.19–0.93] 
 Q439(19.80)46 (23.35)0.93 [0.51–1.70] 0.91 [0.46–1.80] 0.87 [0.44–1.74] 
 Q540(20.30)37 (18.78)0.68 [0.35–1.30] 0.53 [0.24–1.17] 0.58 [0.26–1.28] 
Log-BDE100  0.89 [0.65; 1.20]0.440.95 [0.53; 1.70]0.850.97 [0.54; 1.75]0.91
BDE-153197197      
 Q139(19.80)43 (21.83)Reference0.92Reference0.73Reference0.78
 Q239(19.80)45 (22.84)1.08 [0.58–2.01] 1.30 [0.63–2.68] 1.28 [0.62–2.67] 
 Q340(20.30)22 (11.17)0.52 [0.26–1.01] 0.40 [0.17–0.90] 0.42 [0.18–0.98] 
 Q439(19.80)44 (22.34)1.02 [0.56–1.87] 1.10 [0.55–2.22] 1.12 [0.55–2.29] 
 Q540(20.30)43 (21.83)0.96 [0.52–1.76] 0.85 [0.42–1.74] 0.87 [0.43–1.79] 
log-BDE-153  1.02 [0.62; 1.68]0.940.95 [0.53; 1.70]0.850.97 [0.54; 1.75]0.91
BDE-154197197      
 Q139(19.80)35 (17.77)Reference0.47Reference0.86Reference0.86
 Q239(19.80)38 (19.29)1.09 [0.56–2.11] 0.93 [0.44–1.97] 0.91 [0.43–1.96] 
 Q340(20.30)38 (19.29)1.08 [0.57–2.07] 1.04 [0.50–2.15] 1.06 [0.51–2.21] 
 Q439(19.80)43 (21.83)1.26 [0.66–2.43] 1.14 [0.54–2.41] 1.13 [0.53–2.40] 
 Q540(20.30)43 (21.83)1.24 [0.64–2.40] 1.00 [0.47–2.13] 1.00 [0.46–2.15] 
log-BDE-154  0.99 [0.75; 1.31]0.950.97 [0.70; 1.33]0.830.96 [0.70; 1.33]0.82
PBB-153197197      
 Q139(19.80)47 (23.86)Reference0.31Reference0.33Reference0.29
 Q239(19.80)41 (20.81)0.90 [0.50–1.61] 0.73 [0.38–1.41] 0.67 [0.34–1.31] 
 Q340(20.30)29 (14.72)0.58 [0.31–1.11] 0.49 [0.23–1.07] 0.48 [0.22–1.06] 
 Q439(19.80)51 (25.89)1.06 [0.57–1.97] 0.96 [0.47–1.96] 0.92 [0.45–1.90] 
 Q540(20.30)29 (14.72)0.58 [0.29–1.13] 0.53 [0.24–1.17] 0.50 [0.22–1.13] 
log-PBB-153  1.02 [0.62; 1.68]0.940.95 [0.53; 1.70]0.850.97 [0.54; 1.75]0.91
  1. Model 0: crude estimates;
  2. Model 1: adjusted for total plasma lipid content (ng/L, continuous), smoking status (never vs. ever), physical activity measured in metabolic equivalent tasks (MET)-hour/week (< 35 vs. ≥35), education (≤ 12 years, 12 to 14 years, > 14 years), personal history of benign breast disease (no vs. yes), and family history of breast cancer (none, in first-degree relatives, in extended relatives), parity and age at first full-term pregnancy (FFTP) (no children, 1 or 2 children and < 30 years old at FFTP, ≥3 children and < 30 years old at FFTP, ≥ 30 years old at FFTP), total breastfeeding duration (never, ≤6 or > 6 months), age at menarche (< 13 years vs. ≥ 13 years), current use of menopausal hormone therapy (pre-menopausal, yes, no), and use of oral contraceptives (ever vs. never), menopausal status and age at menopause (pre-menopausal, menopause before age 51, menopause at age 51 or later);
  3. Model 2: Model 1 + adherence score to the Healthy and the Western dietary patterns (above vs. below the median)